Skip to content

Clinical application of nocturnal high-dose levetiracetam in the treatment of BECT

Clinical application of nocturnal high-dose levetiracetam in the treatment of BECT

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100041861
Enrollment
Unknown
Registered
2021-01-08
Start date
2021-02-01
Completion date
Unknown
Last updated
2023-08-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Benign childhood epilepsy with centro-temporal spikes, BECT

Interventions

Group A:2 hours before going to bed at night, 3 doses for 2 stroke and 3 doses for 1 stroke in the morning.
Group B:The total dose should be taken at a time of 2 hours before going to bed at night.
Group C:The total dose was divided into two parts, one hour before bedtime and one dose in the morning, with an interval of 12 hours.

Sponsors

West China Second University Hospital, Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
3 Years to 15 Years

Inclusion criteria

Inclusion criteria: (1) The diagnosis meets the criteria of seizures and epileptic syndrome established by the International Anti-Epilepsy Alliance (ILAE) in 2010; (2) the age of onset is 3-15 years old; (3) seizures occur completely at night or early in the morning; (4) the form of seizures is focal seizures, generalized seizures or focal generalized seizures secondary to generalized seizures; (5) the frequency of seizures is more than 2 / year. (6) EEG was consistent with normal background activity, recurrent spike or sharp waves in the central and / or temporal region; (7) did not receive any antiepileptic drug treatment; (8) before treatment, the blood routine, liver and kidney function and electrolytes of the two groups were normal; (9) this study was submitted to the hospital ethics committee for approval, and all the family members of the patients were informed of the research items and signed the informed consent form.

Exclusion criteria

Exclusion criteria: (1) Cranial space occupying lesions, vascular malformations and other nervous system diseases; (2) complicated with severe heart, liver and kidney insufficiency; (3) poor treatment compliance.

Design outcomes

Primary

MeasureTime frame
Seizure-free efficiency;Occurrence of adverse events;Cognitive function;

Countries

China

Contacts

Public ContactJing Gan

West China Second University Hospital

gordonrachel@163.com+86 13880729998

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026